Viread Related Published Studies
Well-designed clinical trials related to Viread (Tenofovir Disoproxil)
Lack of a significant drug interaction between raltegravir and tenofovir. [2008.09]
Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine. [2008.03]
Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. [2008.01.01]
Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. [2007.11.17]
Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers. [2007.11]
Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137. [2007.07.01]
Fosamprenavir/ritonavir plus tenofovir does not affect amprenavir pharmacokinetics: no effect of tenofovir. [2007.06.19]
Tenofovir Disoproxil Fumarate for Prevention of HIV Infection in Women: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial. [2007.05.25]
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis. [2006.12.15]
Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. [2006.11]
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. [2006.01.19]
Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial. [2006]
Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. [2005.12.01]
Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial. [2005.07.22]
Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. [2005.04]
Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate. [2004.11.01]
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. [2004.07.14]
Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. [2004.06]
Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. [2004.04.01]
Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. [2004.03.01]
Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. [2003.09.02]
Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses. [2003.05.01]
Hydroxyurea does not enhance the anti-HIV activity of low-dose tenofovir disoproxil fumarate. [2001.12.01]
Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. [2001.10]
Well-designed clinical trials possibly related to Viread (Tenofovir Disoproxil)
A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand. [2008.10]
"White coat compliance" limits the reliability of therapeutic drug monitoring in HIV-1-infected patients. [2008.07]
Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine. [2007.10.01]
Other research related to Viread (Tenofovir Disoproxil)
The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. [2008.10.18]
Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir. [2008.08]
Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa. [2008.07.01]
Genetic basis of variation in tenofovir drug susceptibility in HIV-1. [2008.06.19]
Experience with tenofovir disoproxil fumarate for antiretroviral therapy. [2008.05]
Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. [2008.04.15]
Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center. [2008.04.01]
Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. [2008.04]
The pharmacokinetics and viral activity of tenofovir in the male genital tract. [2008.03.01]
The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. [2008.02]
Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. [2008.02]
Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. [2008.02]
Switching patients with lamivudine resistant chronic hepatitis B virus from tenofovir to adefovir results in less potent HBV-DNA suppression. [2008.02]
Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. [2008.02]
Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Compared With Zidovudine/Lamivudine and Efavirenz in Treatment-Naive Patients: 144-Week Analysis. [2008.01.01]
Partial immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and tenofovir-based regimens. [2008]
Predicting tenofovir concentration on the basis of renal factors determined by routine tests. [2007.11]
Bioequivalence of efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen. [2007.10.01]
Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults. [2007.10]
Low-dose tenofovir is more potent than adefovir and is effective in controlling HBV viremia in chronic HBeAg-negative hepatitis B. [2007.08.14]
Bioequivalence of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen. [2007.07.19]
Causes and consequences of hypokalemia in patients on tenofovir disoproxil fumarate. [2007.07.11]
Pharmacokinetics of once-daily tenofovir, emtricitabine, ritonavir and fosamprenavir in HIV-infected subjects. [2007.06.19]
Cutaneous reactions with tenofovir disoproxil fumarate: a report of nine cases. [2007.06.19]
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. [2007.06.19]
Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers. [2007.06]
Long-term follow-up of patients taking tenofovir DF with low-level HIV-1 viremia and the K65R substitution in HIV-1 RT. [2007.03.30]
Tenofovir-induced kidney injury. [2007.03]
Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study. [2007.02]
Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all? [2007.02]
Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir. [2007]
Acute renal failure after initiation of tenofovir disoproxil fumarate. [2007]
Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients. [2006.12.15]
Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. [2006.12.01]
Inhibition of human liver microsomal cytochrome P450 activities by adefovir and tenofovir. [2006.12]
Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. [2006.11.01]
Acquired Fanconi's syndrome associated with tenofovir therapy. [2006.11]
A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. [2006.10.24]
Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/Lamivudine and Efavirenz in Antiretroviral-Naive Patients: Virologic, Immunologic, and Morphologic Changes: A 96-Week Analysis. [2006.10.12]
Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. [2006.10.01]
Evaluation of hypophosphataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy. [2006.10]
Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903. [2006.10]
Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. [2006.09]
Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus. [2006.09]
Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. [2006.08]
Urinary beta2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate. [2006.08]
Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone. [2006.08]
Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir. [2006.07]
Tenofovir disoproxil fumarate for the treatment of HIV infection. [2006.06]
Wild type and YMDD variant of hepatitis B virus: no difference in viral kinetics on lamivudine/tenofovir therapy in HIV-HBV co-infected patients. [2006.05]
Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects. [2006.05]
Short-term safety and tolerability of didanosine combined with high- versus low-dose tenofovir disproxil fumarate in ambulatory HIV-1-infected persons. [2006.04]
Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state. [2006.04]
Use of tenofovir disoproxil fumarate and emtricitabine combination in HIV-infected patients. [2006.04]
Serious renal impairment occurs rarely with use of tenofovir DF. [2006.03]
Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. [2006.03]
Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients. [2006.01.01]
Longitudinal study on mitochondrial effects of didanosine-tenofovir combination. [2006.01]
Efavirenz/emtricitabine/tenofovir disoproxil fumarate: triple combination tablet. [2006]
Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients. [2006]
Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment. [2006]
Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients. [2006]
Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. [2005.12]
Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine. [2005.12]
Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus. [2005.12]
Renal tubular toxicity associated with tenofovir assessed using urine-beta 2 microglobulin, percentage of tubular reabsorption of phosphate and alkaline phosphatase levels. [2005.11.18]
Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. [2005.11.18]
Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites. [2005.10]
Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate. [2005.10]
Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies. [2005.09.15]
Tenofovir trials raise ethical issues. [2005.08]
Systemic and renal pharmacokinetics of adefovir and tenofovir upon coadministration. [2005.08]
Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment--case report and review of literature. [2005.08]
Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study. [2005.07]
|
